Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 16c; offers guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $5.02, $0.16 worse than the analyst estimate of $5.18. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.01 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2024 EPS of $18.15-$19.35, versus the consensus of $19.62. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.2 billion, versus the consensus of $4.081 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Playboy to buy back 16.6M shares from Fortress at $1.05 each
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance